Literature DB >> 3472585

Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

M Eichelbaum, M P Baur, H J Dengler, B O Osikowska-Evers, G Tieves, C Zekorn, C Rittner.   

Abstract

In order to determine on which chromosome the gene controlling human cytochrome P-450 (debrisoquine/sparteine type) is located a linkage study of polymorphic sparteine oxidation (PSO) to various polymorphic markers was carried out. Positive information for linkage between PSO and the P1 blood group was obtained with a maximal LOD-score of LOD = 3.35 for both male and female recombination fraction estimates of theta m = theta f = 0.0. The P1 blood group has been recently mapped to the long arm of chromosome 22. Thus it can be concluded that the gene controlling human cytochrome P-450 (debrisoquine/sparteine) is situated on the long arm of chromosome 22 in close vicinity to P1.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3472585      PMCID: PMC1386095          DOI: 10.1111/j.1365-2125.1987.tb03075.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

Review 1.  Molecular genetics of the fourth component of human complement and steroid 21-hydroxylase.

Authors:  M C Carroll; K T Belt; A Palsdottir; Y Yu
Journal:  Immunol Rev       Date:  1985-10       Impact factor: 12.988

2.  A cytochrome P-450 gene family mapped to human chromosome 19.

Authors:  I R Phillips; E A Shephard; S Povey; M B Davis; G Kelsey; M Monteiro; L F West; J Cowell
Journal:  Ann Hum Genet       Date:  1985-10       Impact factor: 1.670

3.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Report of the Committee on the Genetic Constitution of Chromosomes 20, 21, and 22.

Authors:  P Tippett; J C Kaplan
Journal:  Cytogenet Cell Genet       Date:  1985

5.  Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

Authors:  A Barbeau; T Cloutier; M Roy; L Plasse; S Paris; J Poirier
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

6.  Assignment of the human 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible cytochrome P1-450 gene to chromosome 15.

Authors:  C E Hildebrand; F J Gonzalez; O W McBride; D W Nebert
Journal:  Nucleic Acids Res       Date:  1985-03-25       Impact factor: 16.971

7.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

8.  Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation.

Authors:  F P Guengerich; L M Distlerath; P E Reilly; T Wolff; T Shimada; D R Umbenhauer; M V Martin
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

9.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

View more
  27 in total

Review 1.  Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

Authors:  Leif Bertilsson; Marja-Liisa Dahl; Per Dalén; Ayman Al-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

Review 2.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M R Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

Review 3.  Comparative map for mice and humans.

Authors:  J H Nadeau; M T Davisson; D P Doolittle; P Grant; A L Hillyard; M Kosowsky; T H Roderick
Journal:  Mamm Genome       Date:  1991       Impact factor: 2.957

4.  Oxidative polymorphism of debrisoquine in Parkinson's disease.

Authors:  J Benitez; J M Ladero; F J Jimenez-Jimenez; C Martinez; A M Puerto; M J Valdivielso; A Llerena; J Cobaleda; J J Muñoz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

Review 5.  Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Authors:  A Llerena; J Cobaleda; C Martínez; J Benítez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 6.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

Review 7.  PharmVar GeneFocus: CYP2D6.

Authors:  Charity Nofziger; Amy J Turner; Katrin Sangkuhl; Michelle Whirl-Carrillo; José A G Agúndez; John L Black; Henry M Dunnenberger; Gualberto Ruano; Martin A Kennedy; Michael S Phillips; Houda Hachad; Teri E Klein; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2019-12-09       Impact factor: 6.875

Review 8.  Cytochrome P450 2D6.

Authors:  Ryan P Owen; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

9.  Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.

Authors:  I Roots; J Brockmöller; N Drakoulis; R Loddenkemper
Journal:  Clin Investig       Date:  1992 Mar-Apr

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.